Renier J. Brentjens, MD, PhD, Memorial Sloan-Kettering Cancer Center, New York, NY, outlines the major challenges in CAR T-cell therapies including remission and relapse rate, cost, as well as targeting associated toxicities. This interview was recorded via an online conference call with The Video Journal of Regenerative Medicine (VJRegenMed).

свернуть